Santoro, FrancescoNúñez-Gil, Ivan JViana-Llamas, María CMaroun Eid, CharbelRomero, RodolfoFernández Rozas, InmaculadaAparisi, AlvaroBecerra-Muñoz, Victor ManuelGarcía Aguado, MarcosHuang, JiaMaltese, LudovicaCerrato, EnricoAlfonso-Rodriguez, EmilioCastro Mejía, Alex FernandoMarin, FranciscoRaposeiras Roubin, SergioPepe, MartinoMoreno Munguia, Victor HFeltes, GiselaNavas, Jesus VarasCortese, BernardoBuzón, LuisLiebetrau, CristophRamos-Martinez, RaquelFernandez-Ortiz, AntonioEstrada, VicenteBrunetti, Natale Daniele2023-02-092023-02-092021http://hdl.handle.net/10668/17589No standard therapy, including anticoagulation regimens, is currently recommended for coronavirus disease 2019. Aim of this study was to evaluate the efficacy of anticoagulation in coronavirus disease 2019 hospitalized patients and its impact on survival. Multicenter international prospective registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019). Hospitalized patients with coronavirus disease 2019. Five thousand eight hundred thirty-eight consecutive coronavirus disease 2019 patients. Anticoagulation therapy, including prophylactic and therapeutic regimens, was obtained for each patient. Five thousand four hundred eighty patients (94%) did not receive any anticoagulation before hospitalization. Two-thousand six-hundred one patients (44%) during hospitalization received anticoagulation therapy and it was not associated with better survival rate (81% vs 81%; p = 0.94) but with higher risk of bleeding (2.7% vs 1.8%; p = 0.03). Among patients admitted with respiratory failure (49%, n = 2,859, including 391 and 583 patients requiring invasive and noninvasive ventilation, respectively), anticoagulation started during hospitalization was associated with lower mortality rates (32% vs 42%; p Anticoagulation therapy in general population with coronavirus disease 2019 was not associated with better survival rates but with higher bleeding risk. Better results were observed in patients admitted with respiratory failure and requiring invasive ventilation.enAnticoagulantsCOVID-19Case-Control StudiesCorrelation of DataCross-Cultural ComparisonHemorrhageHospitalizationHumansMulticenter Studies as TopicOutcome Assessment, Health CareProspective StudiesRegistriesRespiration, ArtificialRespiratory InsufficiencyRiskSurvival RateTreatment OutcomeCOVID-19 Drug Treatmentresearch article33861553open access10.1097/CCM.00000000000050101530-0293https://journals.lww.com/ccmjournal/Fulltext/2021/06000/Anticoagulation_Therapy_in_Patients_With.21.aspx